×
About 54,250 results

Novel role for tumor suppressor gene, liver kinase B1, in epithelial mesenchymal transi...
https://doi.org/10.1111/ajt.16903
American Journal of Transplantation : Official Journal Of... Rahman M, Ravichandran R et. al.

Dec 4th, 2021 - Epithelial mesenchymal transition (EMT) has been implicated to play a role in chronic lung allograft dysfunction (CLAD). Liver kinase B1 (LKB1), a tumor suppressor gene, can regulate EMT. However, its role in CLAD development following lung transplantation remains unknown. Using qRT-PCR, biopsies from lung transplant recipients with bronchiolitis obliterans syndrome (BOS) demonstrated significa...

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cance...
https://doi.org/10.1016/j.ygyno.2021.11.013
Gynecologic Oncology; duPont NC, Enserro D et. al.

Dec 4th, 2021 - Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy. Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a pha...

Centromere protein F promotes progression of hepatocellular carcinoma through ERK and c...
https://doi.org/10.1038/s41417-021-00404-7 10.3322/caac.21551 10.20517/2394-5079.2018.18 10.21147/j.issn.1000-9604.2018.06.01 10.1016/S0140-6736(18)30010-2 10.1038/nrc.2016.138 10.1038/nrm3107 10.1158/0008-5472.CAN-05-3389 10.1242/dev.129.7.1715 10.3892/or.2016.5009 10.1002/pmic.201900038 10.1016/j.bbrc.2013.06.021 10.1186/s12935-019-0986-8 10.1080/15384101.2019.1661173 10.7717/peerj.7436 10.1016/j.semcancer.2015.02.006 10.1371/journal.pone.0017794 10.1200/jco.2010.28.15_suppl.3012 10.18632/oncotarget.4879 10.1186/1476-4598-9-237 10.1186/s13046-019-1202-3 10.1038/ncomms11418 10.1002/hep.25900 10.1002/hep.23882 10.1002/1878-0261.12846 10.18632/aging.100296 10.3892/ol.2017.5557 10.1002/cam4.1228
Cancer Gene Therapy; Chen H, Wu F et. al.

Dec 4th, 2021 - Hepatocellular carcinoma (HCC) is one of the deadliest cancer types worldwide. The centromere proteins (CENPs) are critical for the mitosis-related protein complex and are involved in kinetochore assembly and spindle checkpoint signaling during mitosis. However, the clinical significance of CENPs in the recurrence and progression of HCC remains poorly understood. Here, we examined the expressio...

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
https://clinicaltrials.gov/ct2/show/NCT02627443

Dec 3rd, 2021 - PRIMARY OBJECTIVES: I. Assess safety and tolerability of the combination therapy carboplatin, gemcitabine hydrochloride (gemcitabine), and berzosertib (M6620 [VX-970]) in adult women with platinum sensitive recurrent high grade serous or high grade endometrioid ovarian, primary peritoneal or fallopian tube cancer. (Phase I Dose Escalation/Safety Lead-in) II. Determine the dose of the triple the...

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell...
https://clinicaltrials.gov/ct2/show/NCT02699606

Dec 3rd, 2021 - This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esophageal cancer and cholangiocarcinoma.

Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
https://clinicaltrials.gov/ct2/show/NCT02774421

Dec 3rd, 2021 - This study plans to detect the presence of trastuzumab by mass spectroscopy in relapsed posterior fossa ependymoma (PFEPN) tumor specimen pre-treated with a single dose of intrathecal (IT) trastuzumab, as well as to evaluate toxicity of intrathecal trastuzumab in combination with subcutaneous (subQ) Granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with relapsed PFEPN

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition
https://clinicaltrials.gov/ct2/show/NCT04430452

Dec 3rd, 2021 - PRIMARY OBJECTIVE: I. Determine objective response rate (ORR) of durvalumab (D) and D + tremelimumab (T) after radiation therapy (RT) in advanced hepatocellular carcinoma (HCC) patients with progression on prior PD-1 immune checkpoint inhibitor. SECONDARY OBJECTIVES: I. To determine the safety of D and D + T in advanced HCC patients with progression on prior PD-1 immune checkpoint inhibitor. II...

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
https://clinicaltrials.gov/ct2/show/NCT04514484

Dec 3rd, 2021 - PRIMARY OBJECTIVES: I. To determine the safety of combined nivolumab and cabozantinib s-malate (XL184 [cabozantinib]) in human immunodeficiency virus (HIV) patients with advanced solid tumors. II. To determine the feasibility to deliver the combined nivolumab and XL184 (cabozantinib) for a minimum of 4 cycles in at least 75% of the subjects in the expanded cohort with Kaposi sarcoma (KS) or to ...

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04039607

Dec 3rd, 2021 - The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT04145141

Dec 3rd, 2021 - Background: Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide and the one cancer with the fastest rising incidence and mortality in the U.S. PLC consists of two main histological subtypes, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), in which diagnoses and treatment decisions are solely based on their baseline clinical features. Howe...

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
https://clinicaltrials.gov/ct2/show/NCT05003895

Dec 3rd, 2021 - Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second leading cause of cancer-associated mortality with an average life expectancy of 6-9 months Despite the success of several studies showing efficacy in treating HCC, most clinical trials have failed to prove a survival advantage. Adoptive T-cell therapy exploits the natural ability of T-cells to re...

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03304639

Dec 3rd, 2021 - PRIMARY OBJECTIVE: I. To describe the progression-free survival (PFS) of stereotactic body radiation therapy (SBRT) + pembrolizumab (MK-3475) compared to pembrolizumab (MK-3475) alone in advanced/metastatic Merkel cell carcinoma (MCC) patients. SECONDARY OBJECTIVES: I. To describe the PFS of SBRT + MK-3475 compared to pembrolizumab (MK-3475) alone across Response Evaluation Criteria in Solid Tu...

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleu...
https://clinicaltrials.gov/ct2/show/NCT02859415

Dec 3rd, 2021 - Background: Increasing evidence indicates that activation of stem cell gene expression is a common mechanism by which environmental carcinogens mediate initiation and progression of thoracic malignancies. Similar mechanisms appear to contribute to extra-thoracic malignancies that metastasize to the chest. Utilization of pharmacologic agents, which target gene regulatory networks mediating "stem...

A Natural History Study of Children and Adults With Olfactory Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT04755205

Dec 3rd, 2021 - Background: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 cases per year in the United States). ONB most frequently arises in adults aged 20-60 years. Pediatric ONB is particularly rare, with only small case ...

Study on the Efficacy of Radiotherapy Added to Pembrolizumab in Newly Diagnosed Metastatic Head and Neck Cancers
https://clinicaltrials.gov/ct2/show/NCT04747054

Dec 3rd, 2021 - Comparative interventional prospective phase 3, randomised, open-label, multicentric trial comparing the combination of radiotherapy and pembrolizumab to pembrolizumab alone as first line treatment of patients with newly diagnosed head and neck squamous cell carcinoma with synchronous metastases.

Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04645160

Dec 3rd, 2021 - Background: Cholangiocarcinoma (CCA) is an aggressive biliary tract malignancy that remains a clinical challenge with limited treatment options and poor survival. Combination chemotherapy with gemcitabine and cisplatin is the most validated first-line treatment, but the response rate approaches only 22% and median progression free survival is 8 months. Cytoplasmic accumulation of the nuclear ex...

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
https://clinicaltrials.gov/ct2/show/NCT02298959

Dec 3rd, 2021 - PRIMARY OBJECTIVE: I. To determine the safety, tolerability and recommended phase II dosing for the combination of ziv-aflibercept plus MK-3475 (pembrolizumab) in patients with unresectable stage III or stage IV melanoma, renal cell cancer, ovarian cancer, colorectal cancer, or sarcoma. SECONDARY OBJECTIVES: I. To obtain preliminary estimates of progression-free survival at 6 months. II. To obt...

Biomarker-based Study in R/M SCCHN
https://clinicaltrials.gov/ct2/show/NCT03088059

Dec 3rd, 2021 - This is a biomarker-driven trial that will enroll patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy. Based on potential biomarkers and molecular alterations identified in the biopsy from the central platform, patients will be allocated in different cohorts. There will be biomarker-positive patient cohorts ...

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
https://clinicaltrials.gov/ct2/show/NCT03111732

Dec 3rd, 2021 - Background: The most compelling argument in favor of testing immune-based strategies (and anti-Programmed cell death protein 1 (PD1) therapy in particular) in biliary tract cancers (BTC) is that chronic inflammation appears to be the most common etiologic factor in the development of biliary tract cancer. Single-agent activity has been shown for PD1-directed therapy in BTC. Given the potential ...

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-posi...
https://clinicaltrials.gov/ct2/show/NCT04795245

Dec 3rd, 2021 - The primary objective is to confirm Time on Treatment (TOT) related to afatinib treatment as first-line therapy in patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC). The observation in the real-world setting of the time from the start of the first-line afatinib until the end of subsequent treatment in this study will provide insights on t...